Legal & General Group
URGN icon

Legal & General Group’s UroGen Pharma URGN Stock Holding History

Legal & General Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
35,830
+10,658
+42% +$289K ﹤0.01% 2105
2026
Q1 		$453K Buy
25,172
+21,529
+591% +$432K ﹤0.01% 2379
2025
Q4 		$85.3K Sell
3,643
-301
-8% -$6.53K ﹤0.01% 2651
2025
Q3 		$78.7K Sell
3,944
-69
-2% -$1.24K ﹤0.01% 2659
2025
Q2 		$55K Buy
4,013
+138
+4% +$1.32K ﹤0.01% 2696
2025
Q1 		$42.9K Sell
3,875
-15,970
-80% -$170K ﹤0.01% 2747
2024
Q4 		$211K Buy
19,845
+3,920
+25% +$46.9K ﹤0.01% 2656
2024
Q3 		$202K Buy
15,925
+12,311
+341% +$183K ﹤0.01% 2679
2024
Q2 		$60.6K Buy
3,614
+829
+30% +$11.8K ﹤0.01% 2768
2024
Q1 		$41.8K Sell
2,785
-83
-3% -$1.36K ﹤0.01% 2802
2023
Q4 		$43K Buy
2,868
+738
+35% +$9.58K ﹤0.01% 2827
2023
Q3 		$29.8K Sell
2,130
-175
-8% -$2.81K ﹤0.01% 2923
2023
Q2 		$23.9K Buy
+2,305
New +$25.4K ﹤0.01% 3033
2022
Q2 		– Sell
-9,857
Closed -$86K – 3659
2022
Q1 		$86K Buy
9,857
+7,068
+253% +$55.1K ﹤0.01% 2903
2021
Q4 		$27K Hold
2,789
– – ﹤0.01% 3187
2021
Q3 		$47K Hold
2,789
– – ﹤0.01% 2995
2021
Q2 		$42K Hold
2,789
– – ﹤0.01% 3006
2021
Q1 		$54K Sell
2,789
-435
-13% -$9.23K ﹤0.01% 2794
2020
Q4 		$58K Hold
3,224
– – ﹤0.01% 2763
2020
Q3 		$62K Sell
3,224
-803
-20% -$18.2K ﹤0.01% 2621
2020
Q2 		$105K Sell
4,027
-53
-1% -$1.29K ﹤0.01% 2513
2020
Q1 		$73K Sell
4,080
-893
-18% -$24.1K ﹤0.01% 2496
2019
Q4 		$166K Buy
4,973
+746
+18% +$20.4K ﹤0.01% 2441
2019
Q3 		$100K Hold
4,227
– – ﹤0.01% 2518
2019
Q2 		$140K Buy
4,227
+3,319
+366% +$122K ﹤0.01% 2436
2019
Q1 		$33K Buy
908
+536
+144% +$22.5K ﹤0.01% 2892
2018
Q4 		$16K Hold
372
– – ﹤0.01% 3174
2018
Q3 		$17K Hold
372
– – ﹤0.01% 3250
2018
Q2 		$18K Buy
+372
New +$21.6K ﹤0.01% 3215

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Legal & General Group's URGN Position: Q2 2026 in Review

Legal & General Group increased its UroGen Pharma (URGN) stake by 42% in Q2 2026, buying an estimated $289K and bringing the position to 35,830 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

Legal & General Group first reported a position in URGN in Q2 2018 and has held it in 29 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Legal & General Group held 35,830 shares of UroGen Pharma worth $1.32M as of Q2 2026.
  • Legal & General Group bought 10,658 UroGen Pharma shares in Q2 2026, an estimated $289K.
  • UroGen Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2105 holding.
  • Legal & General Group first reported a position in UroGen Pharma in Q2 2018 and has held it in 29 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.